CCT018159 NEW
| Price | $31 | $72 | $113 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-02 |
Product Details
| Product Name: CCT018159 | CAS No.: 171009-07-7 |
| Purity: 99.79% | Supply Ability: 10g |
| Release date: 2026/06/02 |
Product Introduction
Bioactivity
| Name | CCT018159 |
| Description | CCT018159 is a 3,4-diarylpyrazole resorcinol, an ATP-competitive HSP90ATPase inhibitor that inhibits human Hsp90β and yeast Hsp90 with IC50s of 3.2 and 6.6 μM, respectively.CCT018159 inhibits key endothelial and tumor cell functions associated with invasion and angiogenesis. CCT018159 caused cellular inhibition associated with G1 phase block and induced apoptosis. |
| In vitro | CCT018159 (100 nM-10 μM) decreased POMC mRNA levels in AtT-20 cells and ACTH levels in the culture medium of these cells, suggesting that CCT018159 suppresses ACTH synthesis and secretion in corticotroph tumor cells. CCT018159 also decreased cell proliferation and induced apoptosis. FACS analyses revealed that CCT018159 agents increased the percentage of AtT-20 cells in the G2/M phase. CCT018159 decreased cell proliferation, presumably due to the induction of cell death and arrest of the cell cycle in AtT-20 cells.[1] |
| In vivo | CCT018159 (4 mg/mouse; s.c.; ones daily for 14 days; AtT-20-xenografted mice) reduced tumor weight compared to AtT-20-xenografted control mice. CCT018159 also decreased plasma ACTH levels, and POMC and PTTG1 mRNA levels in the tumor cells.[2] |
| Storage | Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 150 mg/mL (425.68 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 10 mg/mL (28.38 mM), Solution. 10% DMSO+90% Saline : < 10 mg/mL (28.38 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. |
| Keywords | HSP90 | CCT-018159 | CCT018159 | CCT 018159 | apoptosis |
| Inhibitors Related | Ethoxyquin | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Formamide | Dimethyl phthalate | Alginic acid | Sildenafil citrate |
| Related Compound Libraries | Apoptosis Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | HIF-1 Signaling Pathway Compound Library | Anti-Breast Cancer Compound Library | Inhibitor Library | Metabolism Compound Library | Bioactive Compounds Library Max | Cytoskeletal Signaling Pathway Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY